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ABSTRACT
Recent evidence suggests that the metastatic spread of head and neck squamous 
cell carcinomas (HNSCC) requires the function of cancer stem cells endowed with 
multipotency, self-renewal, and high tumorigenic potential. We demonstrated that 
cancer stem cells reside in perivascular niches and are characterized by high aldehyde 
dehydrogenase (ALDH) activity and high CD44 expression (ALDHhighCD44high) in HNSCC. 
Here, we hypothesize that endothelial cell-secreted interleukin-6 (IL-6) contributes to 
tumor progression by enhancing the migratory phenotype and survival of cancer stem 
cells. Analysis of tissue microarrays generated from the invasive fronts of 77 HNSCC 
patients followed-up for up to 11 years revealed that high expression of IL-6 receptor 
(IL-6R) (p=0.0217) or co-receptor gp130 (p=0.0422) correlates with low HNSCC 
patient survival. We observed that endothelial cell-secreted factors induce epithelial 
to mesenchymal transition (EMT) and enhance invasive capacity of HNSCC cancer stem 
cells. Conditioned medium from CRISPR/Cas9-mediated IL-6 knockout primary human 
endothelial cells is less chemotactic for cancer stem cells in a microfluidics-based 
system than medium from control endothelial cells (p<0.05). Blockade of the IL-6 
pathway with a humanized anti-IL-6R antibody (tocilizumab) inhibited endothelial 
cell-induced motility in vitro and decreased the fraction of cancer stem cells in vivo. 
Notably, xenograft HNSCC tumors vascularized with IL-6-knockout endothelial cells 
exhibited slower tumor growth and smaller cancer stem cell fraction. These findings 
demonstrate that endothelial cell-secreted IL-6 enhances the motility and survival 
of highly tumorigenic cancer stem cells, suggesting that endothelial cells can create 
a chemotactic gradient that enables the movement of carcinoma cells towards blood 
vessels.
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INTRODUCTION
Head and neck cancer is the sixth most common 
cancer worldwide [1, 2]. HNSCC comprises 90% of all 
tumors of the head and neck region. The overall 5-year 
survival rate is 80% in patients with early stage disease, 
but the rate drops to 20-50% in late stage patients [3]. 
Approximately half of the late stage patients develop 
locoregional or distant metastasis, which significantly 
lowers the survival rates of head and neck cancer patients 
[4]. The understanding of mechanisms driving the invasive 
behavior of tumorigenic HNSCC cells is critical for the 
development of a mechanism-based therapy that prevents 
tumor dissemination.
Cancer stem cell theory postulates that the current 
failure in cancer treatment is due to our inability to 
target tumor cells that are resistant to radiotherapy and 
chemotherapeutic agents [5]. Cancer stem cells are 
uniquely tumorigenic and have the ability to self-renew 
and differentiate. Prince and collaborators first identified 
head and neck cancer stem cells using CD44 expression 
alone [6]. Subsequent report showed that ALDH activity-
based cell isolation selects for cancer stem cells in HNSCC 
[7]. Our group used the two markers together and found 
that the ALDHhighCD44high cells are uniquely tumorigenic 
cancer stem cells in HNSCC [8].
Like normal stem cells, cancer stem cells reside 
in a niche microenvironment to survive and protect the 
self-renewal ability [9]. Our group has shown that head 
and neck cancer stem cells reside in perivascular niche 
[8]. In theory, proximity between cancer stem cells and 
blood vessels makes it easy for the cancer stem cells 
to migrate and invade into blood vessels to initiate 
metastasis. Endothelial cells secrete multiple cytokines 
that affect the behavior of tumor cells. For example, 
endothelial cell-secreted CXCL8 increases the frequency 
of local recurrence in preclinical models of HNSCC 
[10]. In addition, endothelial cell-secreted factors induce 
epithelial-mesenchymal transition (EMT) and migration 
in HNSCC [11], suggesting the endothelial cell-tumor 
cell interaction plays a critical role in cancer progression. 
However, the effect of endothelial cell-secreted factors on 
the invasive behavior of the highly tumorigenic cancer 
stem cells remains to be determined.
IL-6 is a pro-inflammatory cytokine that activates 
JAK/STAT3 pathway. IL-6 level has been correlated with 
tumor progression in multiple cancer types [12–15]. A 
prospective cohort study found that pretreatment serum 
IL-6 level was a predictive marker for recurrence rate and 
overall survival of HNSCC patients [16]. Independent 
studies showed that tumor cells acquire metastatic 
potential through IL-6/STAT3 pathway [17, 18]. IL-6 is 
secreted by many different cells, including T cells, B cells, 
monocytes, endothelial cells, fibroblasts, and some tumor 
cells [19]. Upon inflammatory stimulation, endothelial 
cells secrete high levels of IL-6 [20]. We previously have 
reported that tumor-associated endothelial cells lining 
tumor blood vessels express more IL-6 than the tumor 
cells themselves [21]. However, the role of endothelial 
cell-secreted IL-6 on migratory behavior of head and neck 
cancer stem cells have not been investigated.
Here, we evaluated the significance of endothelial 
cell-secreted IL-6 on head and neck cancer stem cell 
motility and the therapeutic potential of targeting IL-6 
pathway in HNSCC. We observed that expression of 
IL-6R or its co-receptor, gp130 in the invasive front of 
primary HNSCC correlated with poor overall patient 
survival. Endothelial cell-secreted IL-6 induced EMT and 
enhanced migration in head and neck cancer stem cells. 
Collectively, these results demonstrate that endothelial 
cell-secreted IL-6 induces a migratory phenotype in 
head and neck cancer stem cells and suggest that the 
progression of HNSCC towards metastasis or recurrence 
might be prevented or delayed by therapeutic blockage of 
the IL-6 pathway.
RESULTS
Expression of IL-6R or gp130 correlates with 
HNSCC patient outcome
To evaluate the correlation between tumor IL-6R 
and gp130 and the outcome of patients, we used a tissue 
microarray (TMA) containing 77 specimens prepared 
from the invasive front of HNSCC tumors (Supplementary 
Figure 1). Two oral pathologists blinded for experimental 
conditions scored independently these specimens as low 
(score ≤4) and high (score >4) IL-6R or gp130 expression 
based on IHC staining (Figure 1A). We found that high IL-
6R expression in the invasive front of the tumor correlated 
with poor overall survival (log rank test, p=0.0217; Figure 
1B). To control for other known prognostic variables, 
we performed multivariate regression analysis, and IL-
6R maintained significant discriminating ability for 
overall survival (Cox PH model, p=0.0128) in a model 
including age, tobacco use, advanced stage at diagnosis, 
race, sex, and alcohol. gp130 expression also had strong 
correlation with the patient overall survival (log rank 
test, p=0.0422; Cox PH model, p=0.0243) (Figure 1C). 
Immunofluorescence staining showed that IL-6R was 
strongly expressed by most cells at the invasive fronts 
of HNSCC (Figure 1D). As expected, the ALDH1A1-
positive cancer cells are more rarely observed, which is 
consistent with the cancer stem cell hypothesis.
Therapeutic inhibition of the IL-6 pathway 
decreases the cancer stem cells fraction
Informed by the TMA results, we assessed the 
short-term effect of IL-6R inhibition with tocilizumab 
on the fraction of cancer stem cells in preclinical models 
of HNSCC. Unsorted UM-SCC-22B cells were co-
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transplanted with human dermal microvascular endothleial 
cells (HDMEC) in biodegradable scaffolds to generate 
xenograft tumors with human vasculature [23], which is 
amenable to the testing of tocilizumab that does not cross-
react with mouse cells [27]. Two doses of tocilizumab 
(5 kg/mg, IP) were administered within a week period 
before the tumors were surgically removed. Tocilizumab 
treatment had no effect on overall tumor volume when 
compared to IgG treated tumors (Figure 2A). There was no 
change in mouse weight, indicating that tocilizumab was 
Figure 1: Expression of IL-6R or gp130 correlates with HNSCC patient outcome. (A) Representative immunohistochemistry 
staining of low and high expression IL-6R and gp130 and corresponding hematoxilin and eosin (H&E) staining. Scale bars=100 μm. (B) and 
(C) Kaplan-Meier curves of oral squamous cell carcinoma patients over IL-6R and gp130 expression respectively. (D) Immunofluorescence 
staining of ALDH1A1, IL-6R, and DAPI in invasive fronts of two primary patient tumors used in TMA. Scale bars=100 μm.
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well tolerated in mice (Figure 2B). FACS analysis of single 
cell suspensions prepared from the tumor tissues showed 
a significant decrease in ALDHhighCD44high cell population 
in tocilizumab-treated tumors compared to tumors treated 
with IgG (Figure 2C). In accordance with the in vivo data, 
tocilizumab treatment reduced the ALDHhighCD44high cell 
population in UM-SCC-22B cells in vitro (Figure 2D). 
Notably, the concentration of tocilizumab used for in vitro 
experiment did not have cytotoxic effect on tumor cells 
(Supplementary Figure 2A).
Endothelial cell-secreted IL-6 supports cancer 
stem cells and tumor growth
Our group previously reported that head and 
neck cancer stem cells reside nearby the blood vessels, 
suggesting functional crosstalk between the two cell types 
[8]. To test the effect of endothelial cell-secreted IL-6 on 
the fraction of cancer stem cells in vivo, we generated 
IL-6 knockout endothelial cells (sgRNA-IL-6 HDMEC) 
using CRISPR/Cas9 system. ELISA assay showed 80% 
reduction in IL-6 production in sgRNA-IL-6 HDMEC as 
compared to sgRNA-control HDMEC (Figure 3A). The 
IL-6 knockout did not affect the vessel forming ability 
of the endothelial cells, as demonstrated in a Matrigel-
based capillary sprouting assay (Figure 3B). sgRNA-IL-6 
HDMEC were co-implanted with UM-SCC-22B cells 
to generate xenograft tumors. Tumor cells grown with 
sgRNA-IL-6 HDMEC generated smaller tumors compared 
to tumor cells grown with sgRNA-control HDMEC 
(Figure 3C). Regression analysis of the tumor growth rates 
showed that IL-6 knockout in the endothelial cells was 
sufficient to slow down xenograft tumor growth (Figure 
3D). FACS analysis revealed that tumors vascularized 
with sgRNA-IL-6 HDMEC had a smaller fraction of 
ALDHhighCD44high cell population than those vascularized 
with sgRNA-control HDMEC (Figure 3E).
Figure 2: Therapeutic inhibition of the IL-6 pathway decreases the fraction of cancer stem cells. (A) Graph depicting 
the tumor volume of xenografts generated upon transplantation of UM-SCC-22B-tumor cells and treated with 2 doses of tocilizumab 
(arrowheads) (n=12). (B) Mouse weight during the study. Arrowheads indicate the two doses of tocilizumab given before tumors were 
removed. (C) Proportion of ALDHhighCD44high cells in UM-SCC-22B xenograft tumors after tocilizumab treatment detected by FACS 
analysis. (D) FACS analysis result showing the proportion of ALDHhighCD44high cells in UM-SCC-22B cells after tocilizumab treatment for 
24 hours in 10% FBS DMEM in vitro. n.s., not significant; *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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Endothelial cell-secreted IL-6 induces cancer 
stem cell migration
We tested if cancer stem cells had enhanced motility 
compared to non-cancer stem cells in the presence 
of endothelial cell conditioned media (EC CM using 
Transwell migration assay. In the presence of EC CM, more 
ALDHhighCD44high cells migrated than ALDHlowCD44low 
cells (Figure 4A and 4B). Because the magnitude of 
migration induction by endothelial cell-secreted factors 
was stronger in ALDHhighCD44high cells, we focused on 
looking at cancer stem cell motility. In order to evaluate 
the role of endothelial-cell secreted IL-6 on migration of 
cancer stem cells, we treated sorted ALDHhighCD44high 
cells with tocilizumab and allowed the cells to migrate 
in the presence of EC CM. After 24 hours, we found that 
tocilizumab reduced the migration of ALDHhighCD44high 
cells (Figure 4C and 4D; Supplementary Figure 3A). 
We repeated the migration experiments using a different 
approach to verify the reproducibility of the data. Here, 
we used microfluidics device (Figure 4E; Supplementary 
Figure 3B and Supplementary Video) that was previously 
described [24, 25]. EC CM induced strong migration of 
ALDHhighCD44high cells (Figure 4F; Supplementary Figure 
3C). We observed a reduction in cancer stem cell migration 
when the IL-6 pathway was inhibited either with an IL-6 
neutralizing antibody (Figure 4G) or with tocilizumab 
(Figure 4H). To validate the data obtained with antibodies 
target to the IL-6 pathway, we performed migration studies 
using as chemotactic stimulus the EC CM from sgRNA-IL-6 
HDMEC. Again, migration of ALDHhighCD44high cells was 
reduced (Figure 4I; Supplementary Figure 3D).
Endothelial cell-secreted IL-6 induces expression 
of mesenchymal markers in head and neck 
cancer stem cells
The results from migration experiments led to our 
speculation that the enhanced migratory phenotype of 
cancer stem cells might be associated with induction of 
EMT. Indeed, ALDHhighCD44high cells expressed higher 
levels of mesenchymal cell-related proteins, Vimentin and 
Snail, as compared with ALDHlowCD44low cells (Figure 
5A). Interestingly, we found that ALDHhighCD44high 
Figure 3: Endothelial cell-secreted IL-6 supports cancer stem cells and tumor growth. (A) Concentration of IL-6 secreted 
by sgRNA-control or sgRNA-IL-6 HDMEC quantified by ELISA. (B) Representative pictures of sprouts formed by sgRNA-control and 
sgRNA-IL-6 HDMEC on Matrigel. Average number of sprouts per well is shown as bar graph. (C) Graph depicting the average tumor 
volumes (n=10). (D) Repeated measures linear regression estimated mean tumor size prediction line sgRNA-control and sgRNA-IL-6 
HDMEC, respectively, overlayed with individual tumor volume. (E) FACS analysis of ALDHhighCD44high cell proportion in tumors grown 
with sgRNA-control or sgRNA-IL-6 HDMEC. n.s., not significant; *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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cells expressed higher levels of IL-6R and its co-
receptor gp130 than ALDHlowCD44low cells (Figure 
5B). Then, we tested whether the enhanced migratory 
ability of ALDHhighCD44high cells in the presence of EC 
CM correlates with differential EMT level. In order 
to maintain cancer stem cell population after sorting, 
sorted tumor cells were grown in spheres. We observed 
that EC CM induced Vimentin and Snail expression in 
ALDHhighCD44high cells but not in ALDHlowCD44low cells 
(Figure 5C; Supplementary Figure 4B). Similar results 
were reproduced in ALDHhighCD44high cells treated with 
recombinant IL-6 (Figure 5D). Notably, IL-6R blockade 
with tocilizumab inhibited endothelial cell-induced 
Vimentin and Snail expression in ALDHhighCD44high 
cells (Figure 5E; Supplementary Figure 4C). We did not 
observe any change in E-cadherin expression in both 
ALDHhighCD44high and ALDHlowCD44low cells (Figure 5C-
Figure 4: Endothelial cell-secreted IL-6 induces cancer stem cell migration. (A) Representative pictures of migrated UM-SCC-
22B ALDHlowCD44low or ALDHhighCD44high cells stained with crystal violet in Transwell insert after 24 hours of incubation in endothelial 
basal media (EBM) or EC CM. Images taken in 40X magnification. (B) Bar graph depicting migrated ALDHlowCD44low or ALDHhighCD44high 
cells over 24 hour-period in Transwell system. (C) Representative pictures of ALDHhighCD44high cells migrated after tocilizumab treatment 
(2 μg/mL) for 24 hours. Images taken in 40X magnification. (D) Quantification of cells migrated after tocilizumab treatment. (E) Figure 
showing the cell loading and migration in microfluidics devices. Migration frontier was calculated by taking the average of individual cell 
migration distance. (F) EC CM induces migration of ALDHhighCD44high cells in microfluidics device. (G-I), the effect of IL-6 inhibition on 
ALDHhighCD44high cells motility. IL-6 signaling was inhibited by neutralizing IL-6 in EC CM (G) treating tumor cells with tocilizumab (H) 
or using EC CM from sgRNA-IL-6 HDMEC (I). n.s., not significant; *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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5E). This might be because E-cadherin is essential in cells 
surviving in anchorage-independent environment [28].
STAT3 regulates mesenchymal cell markers in 
head and neck cancer stem cells
It is well known that STAT3 is a key downstream 
effector of IL-6 signaling through IL-6R [29]. We observed 
that STAT3 was phosphorylated in ALDHhighCD44high cells 
treated with EC CM or recombinant human IL-6, and that 
tocilizumab inhibited STAT3 phosphorylation (Figure 
5C-5E). Here, we silenced STAT3 in tumor cells using 
shRNA constructs (Figure 6A; Supplementary Figure 
5A). STAT3 knockdown resulted in decreased orosphere-
forming ability of HNSCC cells in ultralow attachment 
plates, suggesting the importance of STAT3 signaling to 
the survival and self-renewal of head and neck cancer stem 
cells (Figure 6B; Supplementary Figure 5B). We tested 
the role of STAT3 on mesenchymal cell-related protein 
expression in HNSCC cells. STAT3 silencing of unsorted 
HNSCC cells was associated with lower Vimentin and 
Snail expressions (Figure 6C). Further, STAT3 silencing 
resulted in a significant decrease in the ALDHhighCD44high 
cell population (Figure 6D; Supplementary Figure 5C). 
Notably, STAT3 silencing inhibited expression of the 
mesenchymal cell-related markers, Snail and Vimentin, in 
ALDHhighCD44high cells (Figure 6E).
DISCUSSION
Tumor dissemination is the major problem in the 
management of patients with advanced head and neck 
cancer. Greater than half of patients with locally advanced 
head and neck cancer develop tumor metastasis or 
relapse, and the survival rate for patients with metastasis 
or relapse is between 5 to 9 months [30]. However, our 
understanding of the mechanisms leading to metastatic 
spread is still limited. It has been recently proposed 
that cancer stem cells play a critical role in metastasis 
development in several cancer types [31–33]. Chinn et 
Figure 5: Endothelial cell-secreted IL-6 induces mesenchymal cell marker expression in head and neck cancer stem 
cells. (A) EMT state of UM-SCC-22B ALDHhighCD44high and ALDHlowCD44low cells. (B) IL-6R and gp130 levels in ALDHhighCD44high cells 
compared to ALDHlowCD44low cells. (C), (D), (E) Effect of EC CM (C), IL-6 (D) and tocilizumab (E) on EMT markers in ALDHhighCD44high 
cells and ALDHlowCD44low cells.
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Figure 6: STAT3 regulates mesenchymal cell markers in head and neck cancer stem cells. (A) Western blot showing STAT3 
knockdown efficiencies of different constructs. The construct #3 was used for the experiments depicted in panels B-E. (B) Bar graph depicts 
average number of orospheres generated from shRNA-control or shRNA-STAT3 UM-SCC-22B. (C) Western blot of STAT3 knockdown 
cells probing for STAT3, pSTAT3, E-cadherin, Vimentin, Snail and GAPDH. (D) FACS analysis of ALDHhighCD44high cell percentage in 
STAT3 knockdown UM-SCC-22B cells. (E) E-cadherin, Vimentin, Snail and GAPDH detection in ALDHhighCD44high cells with STAT3 
knockdown. n.s., not significant; *, P < 0.05; **, P < 0.01; ***, P < 0.001.
Figure 7: Diagram depicting the overall premise of this work. We showed here that endothelial cell-derived IL-6 induces EMT 
and generates a chemotactic gradient for cancer stem cells enabling their movement towards vascular endothelial cells. We postulate 
that this process constitutes the initial step for metastatic dissemination of epithelial tumors, and propose the development of a new 
mechanism-based therapy that is based on the combination of short-term chemotherapy with long-term IL-6 blockade for prevention of 
tumor recurrence/metastasis.
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al. highlighted enhanced potential of cancer stem cells to 
generate lymph node metastasis in HNSCC [34]. Although 
the importance of cancer stem cells in the metastatic 
process is well recognized, it is still unclear how cancer 
stem cells move away from the tumor nests towards blood 
vessels. Here, we demonstrated endothelial cell-secreted 
IL-6 induces cancer stem cell migration and also unveiled 
the therapeutic potential of IL-6 signaling blockage in 
HNSCC.
The importance of IL-6 on cancer pathobiology 
has been well recognized from different types of tumors. 
Serum level IL-6 has been identified as prognostic marker 
in many types of cancer, including ovarian cancer [35], 
prostate cancer [36], breast cancer [14], colon cancer [37], 
melanoma [38] and HNSCC [16]. Here, we observed that 
high IL-6R or gp130 level in the invasive front of tumors 
correlated with poor outcome in HNSCC patients. IL-6 
signaling through IL-6R/gp130 induces robust activation 
of STAT3 signaling. It has been shown that STAT3 
activation enhances invasion and motility of tumor cells 
[39], contributing to the aggressiveness of the tumor. To 
our knowledge, this work is the first to demonstrate that 
high IL-6R or gp130 in the invasive front of the tumor are 
independent predictive markers of HNSCC patient overall 
survival.
With mounting evidence showing the importance 
of IL-6 in tumor biology, IL-6 pathway targeting drugs 
that either block the receptor or binding the ligand have 
been tested. Tocilizumab is a humanized anti-IL-6R 
antibody that inhibits both soluble and membrane-bound 
IL-6R to prevent IL-6 pathway activation. The half-life 
of the antibody is long enough (11-13 days depending 
on the concentration) to allow monthly intravenous 
injections [40]. The drug is well tolerated by the patients 
with minimal side effects [40]. In this study, we tested 
the effect of tocilizumab on HNSCC tumors and found 
that two doses of tocilizumab are sufficient to reduce 
the cancer stem cell fraction. Notably, we performed 
a short-term experiment to single out the effect of IL-
6R inhibition with tocilizumab on the cancer stem cells 
before the therapy caused major differences in overall 
tumor size which would introduce other confounders (e.g. 
larger tumors may contain more necrotic cores, increased 
inflammatory infiltrates...). We have also previously 
reported that inhibition of IL-6R with tocilizumab, or 
direct inhibition of IL-6 with a neutralizing antibody, 
inhibits orosphere formation with HNSCC cells [21, 41]. 
Such results highlight the importance of IL-6 pathway in 
the survival of head and neck cancer stem cells and the 
therapeutic potential of IL-6 inhibition in HNSCC. We 
have previously shown that cisplatin increases the cancer 
stem cell fraction in pre-clinical model of HNSCC [42], 
suggesting a possible explanation for why conventional 
therapies fail to prevent metastasis and recurrence of head 
and neck cancer. The combination of chemotherapy and 
tocilizumab may reduce the tumor size (i.e. debulk the 
tumor) while at the same time ablate the cancer stem cells 
and reduce the chances of tumors to metastasize or relapse.
Our group recently reported that treatment of 
tocilizumab alone slowed the growth rate of xenograft 
model of mucoepidermoid carcinoma tumors, another 
subtype of head and neck cancer [43]. Importantly, the 
tumor growth rate and the fraction of cancer stem cells 
significantly decreased when the tumors were treated 
with tocilizumab and cisplatin together, suggesting that 
combination of existing chemotherapy and IL-6 pathway 
blocking agent may also be beneficial for other head and 
neck cancer patients.
Here, we observed that IL-6 knockout endothelial 
cells resulted in slow tumor growth with smaller 
fraction of cancer stem cells. These results suggest that 
endothelial cells are a key source of the IL-6 that is 
required to maintain the cancer stem cell population in 
the perivascular niche, which perhaps modulates the 
aggressiveness of the tumor. It has been shown that IL-6 
induces EMT in breast cancer models [44], and that it 
promotes metastasis to lymph node and lungs in HNSCC 
[17]. Indeed, we and others reported that inhibition of 
the IL-6 pathway inhibits migration of HNSCC [17, 45]. 
Further, we showed that head and neck cancer stem cells 
express more mesenchymal cell-related proteins and are 
more motile than non-cancer stem cells in response to 
endothelial cell-secreted factors. We demonstrated that 
inhibition of endothelial cell-activated IL-6 pathway 
prevented EMT in cancer stem cells and inhibited their 
migration, unveiling the role of IL-6 on cancer stem cell 
motility. This was observed even in presence of the IL-6 
secreted by the head and neck tumor cells, which we know 
is at lower constitutive levels than the IL-6 expressed by 
the endothelial cells [21]. Interestingly, we did not observe 
induction of migration upon recombinant human IL-6 
treatment alone (data not shown). By itself, IL-6 might 
endow cancer stem cells with migratory phenotype via 
EMT without necessarily acting as chemokine to induce 
cell movement. In contrast, the full endothelial cell-
secreted milieu is very efficient at inducing cancer stem 
cells migration, and within this milieu IL-6 plays a critical 
role as demonstrated in several blocking experiments. 
We conclude that tumor cell migration towards blood 
vessels might be the result of endothelial cell-secreted 
factors working together, and that IL-6 primes the cancer 
stem cells to respond to these factors. We postulate that 
tumor cells may acquire migratory phenotype through the 
IL-6/IL-6R/STAT3 axis, and potent chemokines, such as 
CXCL8, initiate the actual cellular movement to a specific 
direction.
A major challenge in studying cancer stem cells is 
the rarity of this cell population. Head and neck cancer 
stem cell proportion ranges between 0.6-4.5% in primary 
tumors [46] and 1-10% in cell lines [11]. Working with 
such small population of cells makes it difficult to do 
in-depth analysis with most common research tools, as 
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the unique responses of cancer stem cells may not be 
reflected in studies with bulk cells. Recent advances in 
microfluidics technologies have enabled cancer biologists 
to answer questions that were once thought not possible 
to answer. For example, microfluidics devices allowed 
isolating circulating tumor cells from blood samples [47] 
and looking at RNA levels of single cells after different 
treatment [48]. Our group used a novel microfluidics 
migration platform to assess the migration ability of 
cancer stem cells in the presence of EC CM and showed 
the impact of IL-6 pathway in cancer stem cell motility. 
Indeed, the results seen from microfluidic devices were 
in parallel with Transwell migration assays performed 
with sorted cancer stem cells. In comparison to Transwell 
system, microfluidics platform creates gradient of EC 
CM within the migration channel, thus emulating the 
biological environment more accurately. In addition, the 
microfluidics devices allow analysis of the movement of 
single cells during migration process.
In conclusion, we demonstrated here the impact of 
endothelial cell-initiated IL-6 signaling to the migratory 
phenotype of head and neck cancer stem cells, which 
are (Figure 7) the primary mediators of HNSCC tumor 
dissemination. These results suggest the possibility that a 
combination therapy involving conventional chemotherapy 
to debulk the majority of the more differentiated tumor 
cells together with an IL-6 pathway-inhibiting agent to 
ablate cancer stem cells might be beneficial for patients 
with HNSCC.
MATERIALS AND METHODS
Cell culture and reagents
HNSCC cell lines UM-SCC-1 and UM-SCC-22B 
(Tissue Biorepository, University of Michigan Head and 
Neck SPORE) were cultured in Dulbecco’s Modified 
Eagle’s Medium (DMEM; Invitrogen, Carlsbad, CA, 
USA) with 10% FBS, 100 U/mL penicillin, and 100 U/
mL streptomycin (Invitrogen). Primary human dermal 
microvascular endothelial cells (HDMEC; Lonza, 
Walkersville, MD, USA) were cultured in endothelial 
growth medium-2 for microvascular cells (EGM2-MV; 
Lonza). Endothelial cell conditioned medium (EC CM) was 
prepared by collecting supernatant from 24-hour culture 
in serum-free endothelial basal medium (EBM2; Lonza). 
IL-6 signaling pathway was inhibited by treating cells with 
2 μg/mL tocilizumab (Genentech, South San Francisco, 
CA, USA) or EC CM with 1 μg/mL anti-IL-6 neutralizing 
antibody (R&D Systems, Minneapolis, MN, USA).
Tissue microarray, immunohistochemistry and 
immunofluorescence
The preparation of the tissue microarray (TMA) 
slides is described elsewhere [22]. Tissue sections were 
deparaffinized in xylene, washed with 100% ethanol 
and rehydrated with graded ethanol. Antigen retrieval 
was performed by boiling the slides in 1X citrate buffer 
(Thermo Scientific, Fremont, CA, USA) for 20 minutes. 
After slides were cooled down to room temperature, 
the TMA slides were permeabilized for 10 minutes 
at room temperature, and endogenous peroxidase 
activity was inhibited by 10-minute incubation with 
3% hydrogen peroxide (Fisher, Waltham, MA, USA). 
Mouse monoclonal anti-human gp130 (1:100 dilution; 
Santa Cruz) and IL-6Rα (1:100 dilution; Abcam) were 
incubated overnight at 4°C. Chromogenic development 
was achieved by incubating DAB peroxidase substrate 
(Biocare Medical, Concord, CA, USA) for 1-5 minutes 
at room temperature. Two pathologists blind to patient 
information scored the stained sections based on the 
staining intensity (1=no staining, 2=moderate staining, 
3=intense staining) and percentage of positive cells 
(0=0-10%, 1=10-50%, 2=greater than 50%). Final score 
was calculated by multiplying the intensity and positive 
scores. Patients were divided to low (score ≤4) and high 
(score >4) groups. Same deparaffinization and antigen 
retrieval steps were performed for immunofluorescence 
assay. Primary antibodies, ALDH1A1 (1:100 dilution; BD 
Biosciences) and IL-6Rα (1:100 dilution; Santa Cruz), 
were incubated in 4°C overnight. Sections were washed 
with PBS (Invitrogen) and incubated in fluorochrome-
conjugated secondary antibodies for 20 minutes at room 
temperature. After another PBS wash, the slide was 
mounted with DAPI mounting solution and covered with 
coverslip. Nikon Eclipse 80i fluorescence microscope was 
used to take immunofluorescence images, and NIH ImageJ 
was used to process images.
Effect of IL-6R inhibition on tumor growth
1-2x105 UM-SCC-22B cells and 8-9x105 HDMEC 
were seeded in a biodegradable scaffold, as we described 
(23). Loaded scaffold was implanted bilaterally in 
subcutaneous space of the dorsal region of severe 
combined immunodeficient mouse (CB.17.SCID; Charles 
River, Wilmington, MA, USA). Tumors were measured 
weekly, and tumor volume was calculated using the 
formula, (width x width x length)/2. Tocilizumab (5 mg/
kg) or control IgG was given via intraperitoneal injection. 
Mouse weight was measured weekly to observe any 
adverse effect from the treatment.
Fluorescence activated cell sorting (FACS) 
analysis
Head and neck cancer stem cells were isolated as 
described previously [8]. Briefly, single cell suspension 
was prepared from cell culture and resuspended at 
1x106 cells/mL. 5 μL activated Aldefluor (BODIPY-
aminoacetate) (Aldefluor kit; Stem Cell Technologies, 
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Vancouver, BC, Canada) or negative control (DEAB; 
diethylaminobenzaldehyde) was added and incubated at 
37°C for 35 minutes. Then the cells were washed and 
incubated with 5 μL anti-human CD44 (BD Pharmingen, 
Pharmingen, NJ, USA) at 4°C for 30 minutes. 5 μL 
7-aminoactinomycin (BD Pharmingen) was used to select 
out dead cells. Head and neck cancer stem cells were 
defined as ALDHhighCD44high and non-cancer stem cells as 
ALDHlowCD44low.
Migration assay
Transwell migration assay was performed on HTS 
Transwell 96 well permeable support (Corning, Corning, 
NY, USA). Inserts were coated with 0.2% gelatin 
(Sigma-Aldrich, St. Louis, MO, USA) for 15 minutes 
at room temperature prior to cell loading. 5x104 sorted 
ALDHhighCD44high or ALDHlowCD44low cells resuspended 
in 50 μL DMEM were loaded to each insert. 200 μL of 
EC CM was loaded at the bottom well. Transwell plate 
was incubated in cell culture incubator for 24 hours. 
Cells that did not migrate were scrapped off from the 
top of the insert. Migrated cells were stained with 0.5% 
crystal violet (Sigma-Aldrich) solution in 25% methanol 
(Fisher Scientific, Fair Lawn, NJ, USA) for 20 minutes 
at room temperature. Migration was quantified by 
dissolving the crystal violet staining in 10% acetic acid 
(Fisher Scientific) and reading absorbance at 560 nm. 
Alternatively, cell migration assays were performed using 
a microfluidics migration platform that we previously 
developed [24, 25]. Prior to cell loading, the device was 
coated with 0.1 mg/mL collagen solution (rat tail collagen 
type 1; BD Biosciences) for 1 hour to enhance cell 
adhesion and viability. The device was rinsed with PBS 
(Invitrogen) for 1 hour to remove the residual collagen. 
Sorted ALDHhighCD44high or ALDHlowCD44low cells were 
resuspended to 3x105 cell/mL concentration for loading. 
After cell loading, the cell suspension in the left inlet 
was replaced with serum-free DMEM, and EC CM was 
applied to the other inlet to induce migration. Migration 
frontier was measured by taking the average of distances 
the cells migrated after 24 hours of incubation without 
media replenishment.
Generation of IL-6 knockout endothelial cells
IL-6 knockout (sgRNA-IL-6) HDMEC cells were 
generated using CRISPR/Cas9 system [26]. lentiCRISPR 
v2 was a gift from Feng Zhang (Addgene plasmid # 
52961). HEK293T cells were transfected with cocktail 
of pMD2G, psPAX2, and lentiCRISPR v2 with IL-6 
guide sequences (5’-GGTCCAGTTGCCTTCTCCCT-3’ 
and 5’-GTTCCTGCAGTCCAGCCTGA-3’) using 
calcium phosphate method. HDMEC were incubated in 
HEK293T supernatant with 4 μg/mL polybrene (Sigma-
Aldrich) overnight and maintained in 1 μg/mL puromycin 
(InvivoGen, San Diego, CA, USA) EGM2-MV for 
2 weeks. IL-6 knockout efficiency was evaluated by 
performing ELISA (R&D Systems) assay with sgRNA-
IL-6 EC CM.
Generation of STAT3 knockdown HNSCC cells
The calcium phosphate method was used to 
transfect shRNA-control (scramble control) or shRNA-
STAT3 constructs (University of Michigan Vector Core) 
with pMD2G and psPAX2 package vectors into HEK 
293T cells. HNSCC cells were infected with transfected 
HEK293T supernatant overnight with 4 μg/mL polybrene 
(Sigma-Aldrich). Infected tumor cells were cultured in 1 
μg/mL puromycin (InvivoGen) added DMEM medium for 
2 weeks.
Western blot
Sorted ALDHhighCD44high and ALDHlowCD44low cells 
were plated in 6-well ultra-low attachment plate (Corning) 
and incubated for 24 hours. Protein lysates were prepared 
using 1% Nonidet P-40 (NP-40) buffer. 10-20 μg protein 
was loaded in 9-11% SDS-PAGE gel. Primary antibodies 
include: phosphorylated-STAT3 (1:1000 dilution), STAT3 
(1:10,000 dilution), Vimentin (1:500 dilution) and Snail 
(1:1000 dilution) from Cell Signaling (Danvers, MA, 
USA); E-cadherin (1:1000 dilution) and β-actin (1:10000 
dilution) antibody from Santa Cruz; GAPDH (1:10000 
dilution) antibody from Chemicon (Temecula, CA).
Sprouting assay
5X104 HDMEC per well were plated in 12-well 
plates (BD Falcon, NJ, USA) coated with growth factor-
reduced Matrigel (Corning). After 24 hour incubation in 
37°C 5% CO2, the number of capillary-like sprouts was 
counted to determine the impact of IL-6 knockout on in 
vitro angiogenic potential.
Statistical analysis
Tumor microarray survival time data was analyzed 
using log-rank test or multivariate Cox proportional 
hazards models. Tumor volume growth rate was assessed 
using linear mixed effect models to account for repeated 
measurements with an auto-regressive correlation structure 
assuming more correlation among temporally proximate 
observations. The tumor size was log transformed to 
account for exponential tumor volume growth. Model 
fixed effects included time and IL-6 knockout status, 
and model random effects included tumor. Survival 
analysis was performed using the “survival” package and 
mixed effect regression was performed using the “nlme” 
package, both in the statistical software program R version 
3.1.0. Unpaired t test was used to determine significance. 
P ≤ 0.05 was considered significant (n.s., not significant; 
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*, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001). Comparisons in 
means were performed using Prism software (GraphPad 
Software, La Jolla, CA, USA).
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